These results illustrated that DUSP22 is a promising suppressor of NASH and HCC, and maintaining hepatic DUSP22 may serve as a novel therapeutic strategy for the treatment of NASH and fatty liver-associated hepatocarcinogenesis. This evidence concerns the gene DUSP22 and metabolic dysfunction-associated steatohepatitis.